Red Yeast Rice - Food as Medicine
Food is truly an amazing thing. It can wake you up, put you to sleep, tempt you to overindulge, and trigger memories from the past. In some cases, it can even be classified as a drug and pulled from the market.
That's what happened to red yeast rice. It's a bright purple fermented rice that gets its color from being cultivated with the mold Monascus purpureus, and it has been used in traditional Chinese medicine for over a thousand years. For most of that time, it was sold as a treatment for indigestion and a way to "invigorate the blood." Those traditional uses have never been confirmed in modern clinical trials. But in the late 1970s, researchers discovered something genuinely interesting inside it.
Red yeast rice contains a compound called monacolin K, which is chemically identical to the prescription drug lovastatin. It also contains other natural compounds that may add to its effects, so it isn't simply lovastatin in rice form. But monacolin K is the main active ingredient. Clinical trials found that statin drugs like lovastatin lower LDL cholesterol by 24 to 49 percent, depending on the dose. Lovastatin was patented by Merck & Co. and sold under the brand name Mevacor. Red yeast rice began to be promoted as a cheaper, "natural" way to get the same benefit, and small clinical trials suggested it worked.
There was just one problem. Nobody was checking what was actually in the bags and boxes of rice.
The Regulation Failure
Red yeast rice supplements fell under dietary supplement rules, which do not require standardized active ingredient content or drug-level quality controls. Some batches contained substantial amounts of monacolin K. Others had almost none. Analyses of commercial products have found more than a 20- to 40-fold difference in monacolin K content between brands, even when labels claim the same amount of red yeast rice. Some products have been found to contain only trace or negligible amounts of the active compound.
Poor manufacturing created a second problem beyond inconsistent dosing. Badly produced red yeast rice can be contaminated with citrinin, a mycotoxin linked to kidney damage. Consumers buying unregulated supplements had no way to know whether the product they were taking had been tested for it.
Then there were the side effects. Statins can occasionally cause serious muscle and liver injury, and prescription products carry mandatory warnings and monitoring recommendations. Red yeast rice products with similar monacolin K levels carried no comparable warnings and required no physician oversight.
In 1998, the FDA stepped in. The agency's position was that products containing significant amounts of monacolin K were functioning as unapproved drugs and could not legally be marketed as dietary supplements. After a legal battle over a product called Cholestin, the FDA prevailed. Products with more than trace monacolin K were effectively pushed off the market.
What We Lost
Here's where the story gets complicated, and where the real loss becomes clear.
We know red yeast rice can work. A landmark clinical trial called the China Coronary Secondary Prevention Study enrolled nearly 5,000 patients with prior heart attacks and followed them for four and a half years. Patients taking Xuezhikang, a standardized red yeast rice extract containing about 10 to 12 milligrams of total monacolins daily, saw major coronary events drop from 10.4 percent in the placebo group to 5.7 percent, a 45 percent relative reduction.
A 2020 meta-analysis covering seven trials and nearly 11,000 patients confirmed that red yeast rice significantly lowered the risk of nonfatal heart attack, the need for revascularization, and sudden death. It's worth noting that these studies used standardized pharmaceutical-grade preparations, not the variable supplements sold in American stores.
The tragedy isn't that red yeast rice is a fraud. The tragedy is that a well-documented option was caught between two frameworks with no good landing spot. What was actually lost wasn't a therapy. Lovastatin still exists and is available by prescription. What was lost was access to a non-prescription version with a meaningful evidence base, in a market that lacked the quality controls to make it safe.
The supplement industry responded to the FDA's actions not by improving standards but by stripping out the active ingredient and continuing to market the product as though nothing had changed. Many companies still link to the old cholesterol-lowering studies without disclosing that the product they're currently selling no longer contains what made those studies work.
Where Things Stand Today
In Europe, regulators moved differently. The European Commission now limits red yeast rice supplements to no more than 3 milligrams of monacolins per daily serving and requires label disclosure. In July 2024, the EU revoked the health claim for monacolin K at the 10-milligram dose. As of early 2025, the European Food Safety Authority has concluded that a safe intake level for monacolins from red yeast rice cannot be established, and that adverse effects may occur at doses as low as 3 milligrams per day. A full prohibition is being considered.
In the United States, the FDA's enforcement position hasn't changed. Many red yeast rice products on American store shelves now contain only trace or highly variable amounts of monacolin K, making their cholesterol-lowering effect unreliable at best.
What This Means for You
If you have high cholesterol, the red yeast rice supplements sold in most American health food stores and pharmacies are unlikely to produce consistent results. You may be a candidate for prescription statins, but that's a conversation to have with your doctor based on your full cardiovascular risk profile.
The most effective lifestyle approach to lowering cholesterol combines dietary changes, weight management, and exercise. Regular aerobic exercise and combined aerobic and resistance training can produce meaningful improvements in cholesterol and triglycerides. Studies typically show effects in the single-digit to low-teens percentage range, and the cardiovascular benefits go well beyond lipid numbers alone.
If your doctor recommends red yeast rice as a cholesterol treatment, it's worth asking a direct question: given that many American products contain only trace or highly variable amounts of the active ingredient, what's the rationale for choosing it over a prescription statin with standardized dosing and established monitoring?
It's a reasonable question, and a good doctor will have a reasonable answer. Some physicians do recommend standardized red yeast rice preparations for patients who cannot tolerate conventional statins, and that conversation is worth having if it applies to you.
For more information about cholesterol, read our "Combating Cholesterol" article by clicking here.
Reference Links:
Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction
Zongliang Lu, MD, PhDa ∙ Wenrong Kou, MDa ∙ Baomin Du, MDb ∙ Yangfeng Wu, MDc ∙ Shuiping Zhao, MD, PhDd ∙ Osvaldo A. Brusco, MDe ∙ John M. Morgan, MDf ∙ David M. Capuzzi, MD, PhD
The American Journal of Cardiology - Coronary Artery Disease, Published Volume 101, Issue 12 p1689-1693 June 15, 2008
Click Here for the Study: https://doi.org/10.1016/j.amjcard.2008.02.056
Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials
Bunleu Sungthong, Chenchira Yoothaekool, Sornsalak Promphamorn & Wiraphol Phimarn
Scientific Reports, Published 17 February 2020
Click Here for the Study: https://www.nature.com/articles/s41598-020-59796-5
Marked Variability of Monacolin Levels in Commercial Red Yeast Rice Products
Buyer Beware!
Ram Y. Gordon, MD; Tod Cooperman, MD; William Obermeyer, PhD
David J. Becker, MD
JAMA Internal Medicine, Published Online: October 25, 2010
Click Here for the Study: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/226109
Variability in strength of red yeast rice supplements purchased from mainstream retailers
Pieter A Cohen, Bharathi Avula & Ikhlas A Khan
European Journal of Preventive Cardiology, Published 29 August 2020
Click Here for the Study: https://doi.org/10.1177/2047487317715714
The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis
Neil A. Smart, David Downes, Tom van der Touw, Swastika Hada, Gudrun Dieberg, Melissa J. Pearson, Mitchell Wolden, Nicola King & Stephen P. J. Goodman
SPORTS MEDICINE, Published 27 September 2024
Click Here for the Study: https://link.springer.com/article/10.1007/s40279-024-02115-z
Call for a FREE Consultation (305) 296-3434
CAUTION: Check with your doctor before
beginning any diet or exercise program.
12/11/2011
Updated 6/23/2026
